Muutke küpsiste eelistusi

E-raamat: Progress in Medicinal Chemistry

Edited by (Professor, University of Sussex, Brighton, UK), Edited by (WITNET LTD, Cambridge, UK)
  • Formaat: EPUB+DRM
  • Sari: Progress in Medicinal Chemistry
  • Ilmumisaeg: 24-Jun-2022
  • Kirjastus: Elsevier - Health Sciences Division
  • Keel: eng
  • ISBN-13: 9780323989046
Teised raamatud teemal:
  • Formaat - EPUB+DRM
  • Hind: 189,74 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
  • Formaat: EPUB+DRM
  • Sari: Progress in Medicinal Chemistry
  • Ilmumisaeg: 24-Jun-2022
  • Kirjastus: Elsevier - Health Sciences Division
  • Keel: eng
  • ISBN-13: 9780323989046
Teised raamatud teemal:

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

Progress in Medicinal Chemistry, Volume 61 provides a review of eclectic developments in medicinal chemistry, with each chapter written by an international board of authors.
  • Provides extended, timely reviews of topics in medicinal chemistry
  • Contains targets and technologies relevant to the discovery of tomorrow’s drugs
  • Presents analyses of successful drug discovery programs
Contributors in this volume include:
Kat Van Rietschoten
Karthik Iyer
Rick Cousins
Werngard Czechitzky
Charlotte Hardy
Dr David Witty has more than 20 years experience in the pharmaceutical industry as a medicinal chemist and project leader working principally in areas of anti-infectives, metabolic diseases, cognition and pain, delivering clinical candidates for several conditions. He led IT Strategy within the Neurology division of GSK, developing and deploying the first Electronic Notebooks for drug discovery to sites in the UK and Singapore. He has contributed more than 90 scientific papers, reviews, patents and books on medicinal and synthetic chemistry.In 2010 David and several colleagues successfully raised $35M in venture funding to found Convergence Pharmaceuticals, a specialist ion channel company focused on the development of novel treatments for pain, based in Cambridge UK. David presently leads their discovery programme and manages scientific operations within the business.David is chairman of the Fine Chemicals Group of the Society of Chemical Industry, with responsibility for the delivery of conferences, seminars and training courses for chemists throughout the UK and Europe, and advising parliamentary bodies on matters of relevance to the UK chemical industry.Since 2008 David has been a STEM ambassador for SETPOINT, introducing school students at both primary and secondary level to the excitement and possibilities of pursuing scientific careers, through workshops, lectures and competitions. Professor Brian Cox is at University of Sussex, Brighton, UK